choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.


Hop on Facility in Horizon Europe

The Hop on Facility call will provide the possibility for legal entities from low R&I performing countries (=widening countries) to join already selected collaborative projects under Pillar 2 and the EIC Pathfinder of Horizon Europe.

Programmes Widening/Spreading   HorizonEU L+F  

Published on | 2 years ago

Last updated on | 8 months ago

Author Do you have an additional question? Or spotted a mistake? Don't hesitate to contact me!
Image of Man Hei To
Man Hei To


In order to stimulate the participation of widening countries in Horizon Europe in particular in the Pillar 2 Actions, the European Commission has created the Hop On Facility call (HORIZON-WIDERA-2023-ACCESS-06-01). This call will be funded through the Work Programme Widening participation and strengthening the European Research Area and contributes to the inclusiveness ambition of the future European Research Area. This call will provide the possibility for legal entities from low R&I performing countries (=widening countries) to join already selected collaborative projects, subject to the agreement of the respective consortium and provided that legal entities from such countries are not participating in it yet.

Widening Countries

As defined in the Horizon Europe regulation the low performing R&I countries or the so called widening countries are Bulgaria, Croatia, Cyprus, Czechia, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Portugal, Romania, Slovakia, Slovenia and all Associated Countries with equivalent characteristics in terms of R&I performance and the Outermost Regions (defined in Art. 349 TFEU).

The Horizon Europe Associated Countries that are considered as widening countries are : Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Kosovo, Moldova, Montenegro, Morocco, North Macedonia, Serbia, Tunisia, Turkey and Ukraine.

How does it work?

A consortium under Pillar 2 Actions and the EIC Pathfinder of Horizon Europe with a valid grant agreement but without a partner from a widening country in the consortium yet can apply to include a legal entity from a widening country in their consortium. The application to include a partner from a widening country needs to be submitted by the coordinator of the consortium. All consortium partners need to agree with the inclusion of this new partner from a widening country. The application needs to describe in detail the profile of the new partner and the role of this partner in the project and the R&I relevance and  complementarity of this new partner also needs to be demonstrated in the application. All the information will have to be added in a track changes document based on the Description of the Action (DOA). The selected applications will be invited to submit an amendment for accession of the new partner, the modification of the description of the action and upgrade of the budget.

On the Funding and Tenders Portal you will find a list of the funded projects in Pillar 2 and the EIC Pathfinder that are eligible for the Hop On Call. Flemish coordinators that need help with finding suitable partners from widening countries dont't hesistate to contact your NCP Widening, Man Hei To (


The European Commission foresees a budget between 200K EUR and 500K EUR per project. This additional top-up will be added to the initial budget of the existing consortium. However this budget increase should be exclusively spent at the benefit of the new partner with the exception of a coordination fee of up to 10% of the increased budget to be allocated to the coordinator of the consortium.

Expected impact

The proposals for this additional top-up will need to contribute to the following expected impacts:

  • At system level: mobilise excellence and increase visibility of the participants from the Widening countries, improve knowledge circulation, and reduce lack of participation of Widening countries in thematic domains.
  • At organisation level: open up silos of established closed consortia and improve research excellence of the Widening country’s institutions in specific fields.
  • At the level of the beneficiary: create new competencies and skills (from working in transnational projects) including on research management and dissemination and exploitation of results.

Opening date and deadlines

This call is open from 10 January 2023 and will have two closing dates: on 28 September 2023 and 26 September 2024.


- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders


image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.